The generic version of Jadenu would potentially be available after 21 November, 2034. This release date is contingent on the expiration of the patent US9283209 titled 'Oral formulations of deferasirox'.
Jadenu, with its active ingredient deferasirox, is extensively used in treating chronic iron overload due to multiple blood transfusions. It functions by helping the body to remove excess iron.
The generic release of Jadenu is influenced by its patents. The drug's last patent, 'Oral formulations of deferasirox' (US9283209), is due to expire on 21 November, 2034. Ahead are the details of the patent: